Evidence map›Paper›PMID 39286797›Full record

ArticleOncoimmunology2024

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy.

Vishnu Vijay Vijayan, Preethi Gopalakrishnan Nair, Shashi Gujar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Vishnu Vijay VijayanDepartment of Pathology, Dalhousie University, Halifax, Canada.
Preethi Gopalakrishnan NairDepartment of Pathology, Dalhousie University, Halifax, Canada.
Shashi GujarDepartment of Pathology, Dalhousie University, Halifax, Canada.ORCID 0000-0002-5427-0829

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD38, a multifunctional enzyme involved in NAD+ catabolism, is hypothesized to act as a metabolic checkpoint for antitumor CD8 T cells. A recent study discovered that, apart from its direct metabolic mechanisms, CD38-mediated RyR2-AKT-TCF1 signaling regulates responsiveness to anti-PD1 cancer therapy at the molecular level. These findings advocate multiprong CD38 targeting to overcome resistance to immune checkpoint blockade therapy.

Indexed as

ADP-ribosyl Cyclase 1Immune Checkpoint InhibitorsNeoplasmsProgrammed Cell Death 1 ReceptorAnimalsCD8-Positive T-LymphocytesHepatocyte Nuclear Factor 1-alphaHumansMembrane GlycoproteinsProto-Oncogene Proteins c-aktSignal TransductionADP-ribosyl Cyclase 1CD38 protein, humanHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanImmune Checkpoint InhibitorsMembrane GlycoproteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktCancer immunotherapyCD38immune checkpoint blockademetabolismPD1T cell exhaustionTCF1

Identifiers

PMID39286797
PMCPMC11404572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.